Droperidol , ≥98% , 548-73-2

Synonym(s):
1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone;Droperidol

CAS NO.：548-73-2

Empirical Formula: C22H22FN3O2

Molecular Weight: 379.43

MDL number: MFCD00083290

EINECS: 208-957-8

PRODUCT Properties

• Melting point: 148-149°C
• Density: 1.2154 (estimate)
• storage temp.: 2-8°C
• solubility: Practically insoluble in water, freely soluble in dimethylformamide and in methylene chloride, sparingly soluble in ethanol (96 per cent).
• form: Solid
• pka: 7.64(at 25℃)
• color: Pale Yellow to Pale Beige
• Water Solubility: 4.1mg/L(30 ºC)
• CAS DataBase Reference: 548-73-2(CAS DataBase Reference)
• EPA Substance Registry System: 2H-Benzimidazol-2-one, 1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro- (548-73-2)

Description and Uses

D roperidol is a butyrophenone that has potent antidopaminergic (D2) activity and mild α2-blocking actions. It produces sedation and anxiolysis and is an effective antiemetic. A dverse effects include vasodilatation and hypotension, and at higher doses, dystonic reactions can occur. D roperidol was used for premedication and in neuroleptanaesthesia until reports of death from long QT syndrome led to its withdrawal in 2001. It has recently been reintroduced and licenced at lower doses for prevention of postoperative nausea and vomiting. D roperidol has an onset of 3–10 min after i.v. injection and duration of action of 6–12h. It undergoes hepatic metabolism, but approximately 10% of the drug is excreted unchanged in the urine.

A D1DR and D2DR inhibitor.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: Xn
• Risk Statements: 22
• Safety Statements: 36
• RIDADR: 3249
• WGK Germany: 3
• RTECS: DE2100000
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 2933995800
• Hazardous Substances Data: 548-73-2(Hazardous Substances Data)
• Toxicity: LD50 oral in rat: 750mg/kg